Reuters logo
BRIEF-Roche CEO expects biosimilar competition from 2015
January 30, 2014 / 6:55 AM / in 4 years

BRIEF-Roche CEO expects biosimilar competition from 2015

ZURICH, Jan 30 (Reuters) - Roche Holding AG : * CEO says expects biosimilars for rituxan in 2016 and herceptin in 2015 * CEO says net debt to assets ratio is back within target range, at 11 percent * CEO says will continue to look out for bolt on buys, would not want to give a

specific range

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below